Pyxis Oncology, Inc. (NASDAQ:PYXS) Receives $7.75 Average PT from Analysts

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS) have received a consensus rating of “Moderate Buy” from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $7.75.

PYXS has been the topic of a number of research analyst reports. Guggenheim initiated coverage on Pyxis Oncology in a report on Wednesday, September 3rd. They set a “buy” rating and a $5.00 target price on the stock. Zacks Research upgraded Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a report on Monday, October 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $5.00 target price on shares of Pyxis Oncology in a report on Tuesday, August 19th. Finally, Wall Street Zen cut Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd.

Institutional Trading of Pyxis Oncology

A number of hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE boosted its position in shares of Pyxis Oncology by 20.3% in the 4th quarter. Bank of America Corp DE now owns 53,745 shares of the company’s stock worth $84,000 after purchasing an additional 9,062 shares in the last quarter. Catalyst Funds Management Pty Ltd bought a new stake in shares of Pyxis Oncology in the 2nd quarter worth approximately $26,000. Kingstone Capital Partners Texas LLC bought a new stake in shares of Pyxis Oncology in the 2nd quarter worth approximately $37,000. XTX Topco Ltd bought a new stake in shares of Pyxis Oncology in the 2nd quarter worth approximately $40,000. Finally, Velan Capital Investment Management LP bought a new stake in shares of Pyxis Oncology in the 2nd quarter worth approximately $44,000. 39.09% of the stock is owned by institutional investors.

Pyxis Oncology Stock Performance

PYXS stock opened at $3.58 on Friday. Pyxis Oncology has a fifty-two week low of $0.83 and a fifty-two week high of $5.39. The business’s 50 day moving average price is $2.12 and its two-hundred day moving average price is $1.48. The company has a market capitalization of $222.03 million, a price-to-earnings ratio of -2.24 and a beta of 1.33.

Pyxis Oncology (NASDAQ:PYXS) last posted its earnings results on Thursday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.06. The firm had revenue of $2.82 million for the quarter. Sell-side analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.